Palbociclib was granted accelerated approval in 2015 with the aromatase inhibitor letrozole for the treatment of ER+/HER2- advanced breast cancer as an initial endocrine-based therapy in postmenopausal women. This evidence concerns the gene ERBB2 and breast carcinoma.